# VA San Diego Healthcare System

## Dermatology Drug Formulary

**Restricted Drugs in Italics**

### Medication Monitoring in *Asterisk*

### ACNE PRODUCTS (topical)
- Erythromycin 2% solution (60ml)
- Clindamycin 1% swab (#60)
- Benzoyl Peroxide 2.5%, 5%, 10% gel (60g)
- Tretinoin 0.025%, 0.05%, 0.1% (60g)

### ACNE PRODUCTS (oral)
- Doxycycline 50, 100 mg caps
- Minocycline 50, 100 mg caps
- *Isotretinoin* 10, 20, 30, 40 mg tabs

### ANTI-INFECTIVES (topical)
- Bacitracin 500 U (30g)
- Bacitracin/polymyxin 50/10000 U/gm (30g)
- Clindamycin phosphate 1% swab (#60)
- Mupirocin 2% oint (22g)
- Silver sulfadiazine 1% cream (50, 85, 400g)
- Sulfacetamide 10% lotion (120ml)

### ANTI-INFECTIVES (oral)
- Dicloxacillin 250, 500, 750 mg tabs
- Ciprofloxacin 150, 300 mg caps
- Clindamycin 150, 300 mg caps
- Cephalexin 250, 500 mg caps
- Flucloxacillin 250, 500 mg tabs
- Levofoxacin 250, 500, 750 mg tabs

### ANTI-ITCH (topical)
- Camphor 0.5%/Menthol 0.5% (Sarna) Lotion (7.5oz)
- Colloidal Oatmeal powder packet (#8)

### ANTI-ITCH (oral)
- Cetirizine 10 mg tabs
- Diphenhydramine 25m, 50 mg caps
- Doxepin 10, 25 mg caps
- Hydroxyzine HCL 10, 20, 50 mg tabs
- Loratadine 10 mg tabs

### ANTI-FUNGAL (oral)
- Fluconazole 150, 200 mg tabs
- Terbinafine 250 mg tabs

### ANTI-FUNGAL (topical)
- Clotrimazole 1% cream (15g)
- Ketoconazole 2% cream (30g), shampoo (120ml)
- Metronidazole 0.75% cream (45g)
- Miconazole 2% cream (30g), tincture (30ml)
- Nystatin Powder (30g)
- Podofilox 0.5% soln (3.5ml)
- Terbinafine 1% cream (30g)

### ANTI-PSORIATICS (topical)
- Coal tar Emulsion 7.5% (180ml)
- Coal tar Shampoo 0.5% (255ml), 1% (180ml)
- Calcipotriene 0.005% cream (60g)

### ANTI-PSORIATICS (oral)
- Acitretin 10, 25 mg caps
- *Azathioprine* 50 mg tabs
- *Methotrexate* 2.5 mg tabs

### CORTICOSTEROIDS (topical)
- Clobetasol 0.05% cream (60g)
- Desonide 0.05% cream (60g)
- Fluocinolone acetonide 0.01% soln (60ml)
- Fluocinolone 0.05% cream, oint (60g)
- Flurandrenolide (Cordran) 4mg/sqcm tape (80in)
- Halobetasol 0.05% cream (50g), oint (15,50g)
- Hydrocortisone 1%, 2.5% cream (30g)
- Triamcinolone 0.025% cream (15g), oint (80g)
- 0.1% cream (15g), oint (15g, 45.45g)

### CORTICOSTEROIDS (oral)
- Prednisone 5, 10, 20 mg tabs
- Dexamethasone 0.5, 0.75, 2, 4 mg tabs

### SCABICIDES/PEDICULOCIDES
- Permethrin 1% liquid (60ml), 5% cream (60g)
- Ivermectin 3mg tabs

### EMOLLIENTS/KERATOLYTICS
- Ammonium lactate 12% lotion (225ml)
- Petrolatum oint (30, 454g)
- Urea 10% lotion (240ml)
- Salicylic acid 3% shampoo (120ml)
- 40% plaster (#1)
- Salicylic acid/Sulfur 2%/2% shampoo (120ml)

### TOPICAL ANESTHETICS
- Capsaicin 0.025%, 0.1% cream (60g)
- Dibucaine 1% oint (30g)
- Lidocaine 4% cream (30g), 5% oint (35g)
- Lidocaine/Prilocaine 2.5%/2.5% cream(30g)
- Pramoxine 1% lotion (227ml)
- Menthol/M-salicylate 10-15% cream (90g)

### Miscellaneous
- Calamine Lotion (180ml)
- Folic acid 1mg tabs
- Hydrophilic (Eucerin) Cream (120, 454g)
- Hydroquinone 4% cream (30g)
- Lanolin hydrous oint (30g)
- Fluorouracil 2% solution (10ml)
- Sunscreen (Zinc Oxide) SPF 30-50 lotion (120ml)
- Zinc Oxide 20% oint (60g)
- Hydroxychloroquine 200 mg tabs

---

1. Restricted to inadequate response or documented ADR to clotrimazole
2. Restricted to permethrin failure or crusted scabies
3. Restricted to DJD/zoster/peripheral neuropathy

---

*VA San Diego Outpatient Pharmacy*

Hours: Monday to Friday 8:30am to 6:30pm.
Closed on weekends & federal holidays.
Phone number: 888-229-7209
Fax number: 888-552-7522

VA SAN DIEGO PROHIBITS THE DISTRIBUTION OF SAMPLES TO PATIENTS
Update 6/2017

---

*Prescribing Guideline*

- All Choice Program prescriptions require a Choice Network Provider Authorization form.
- Other agents may be available, but are restricted to VA criteria for use.
- For restricted medications in italic and those restricted to VA criteria for use, please annotate rationale for use.

Please visit the following link for more information on medication criteria:

http://www.pbm.va.gov/clinicalguidance/criteriaforuse.asp
<table>
<thead>
<tr>
<th>Drug Monitoring</th>
<th>Laboratories</th>
<th>Frequency of Monitoring</th>
<th>Required/Recommended</th>
<th>Black Box Warning/ Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isotretinoin (Accutane)</td>
<td>Serum HCG</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td>Teratogenic. Contraindication in pregnancy. Must be prescribed under I pledge Monitoring Program. Increased risk of depression/suicidality.</td>
</tr>
<tr>
<td></td>
<td>Monthly</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At completion of therapy</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 month post-discontinuation</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs &amp; Lipid panel</td>
<td>Baseline (w/in 6 months)</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every 4 weeks until response established</td>
<td>Recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine 6-Mercaptopurine</td>
<td>CBC</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td>Metabolic acidosis may occur at any time during treatment but especially early in treatment and in patients with preexisting conditions such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, or in patients receiving concomitant drug therapies which have additive bicarbonate lowering effects and in ketogenic diets.</td>
</tr>
<tr>
<td></td>
<td>Weekly for the 1st month</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Every other week for month 2 &amp; 3</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monthly thereafter</td>
<td>Required</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TMPT (Thiopurine methyltransferase)</td>
<td>Baseline prior to dispensing</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs</td>
<td>Baseline prior to dispensing</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bi-weekly for the 1st month</td>
<td>Recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monthly thereafter</td>
<td>Recommended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>CBC, SCR, LFTs, Alk Phos</td>
<td>Baseline (w/in 6 months)</td>
<td>Required</td>
<td>Bone marrow suppression, hepatotoxicity, lung toxicity, malignant lymphomas, tumor lysis syndrome, skin reactions and fetal opportunistic infections have been reported. Preservative containing formulations or diluents not used for intrathecal or high dose use. Teratogenic. Not recommended for women of child bearing potential unless benefit-risk ratio is acceptable. Elimination is reduced in impaired renal fnx, ascites, or pleural effusions &amp; requires dose reduction.</td>
</tr>
<tr>
<td></td>
<td>CBC</td>
<td>Every 6 months</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LFTs, SCR</td>
<td>Every 8 weeks</td>
<td>Recommended</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chest Xray</td>
<td>Baseline within prior year</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HCG</td>
<td>Baseline prior to dispensing</td>
<td>Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hepatitis B and C serology in high risk patients</td>
<td>Baseline (w/in 6 months)</td>
<td>Recommended</td>
<td></td>
</tr>
</tbody>
</table>